GlaxoSmithKline plc (NYSE:GSK) has been assigned a consensus rating of “Hold” from the twenty-one analysts that are currently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, ten have given a hold recommendation and six have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $37.71.

A number of equities research analysts have issued reports on the company. UBS raised GlaxoSmithKline from a “neutral” rating to a “buy” rating and boosted their price target for the company from $35.04 to $35.85 in a research report on Monday, November 27th. Cowen set a $38.00 price target on GlaxoSmithKline and gave the company a “hold” rating in a research report on Monday, December 11th. Argus reissued a “buy” rating and set a $50.00 price target on shares of GlaxoSmithKline in a research report on Thursday, August 31st. Zacks Investment Research downgraded GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. Finally, Bank of America downgraded GlaxoSmithKline from a “buy” rating to a “neutral” rating in a research report on Thursday, October 26th.

In related news, major shareholder Plc Glaxosmithkline bought 428,571 shares of the firm’s stock in a transaction dated Monday, November 6th. The stock was bought at an average price of $14.00 per share, with a total value of $5,999,994.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 10.00% of the stock is owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the stock. 1st Global Advisors Inc. lifted its stake in shares of GlaxoSmithKline by 0.4% in the second quarter. 1st Global Advisors Inc. now owns 5,271 shares of the pharmaceutical company’s stock worth $227,000 after acquiring an additional 19 shares in the last quarter. King Luther Capital Management Corp lifted its stake in shares of GlaxoSmithKline by 1.0% in the second quarter. King Luther Capital Management Corp now owns 5,432 shares of the pharmaceutical company’s stock worth $234,000 after acquiring an additional 55 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its stake in shares of GlaxoSmithKline by 1.9% in the second quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company’s stock worth $137,000 after acquiring an additional 64 shares in the last quarter. Strategic Global Advisors LLC lifted its stake in shares of GlaxoSmithKline by 0.6% in the second quarter. Strategic Global Advisors LLC now owns 12,179 shares of the pharmaceutical company’s stock worth $525,000 after acquiring an additional 75 shares in the last quarter. Finally, PagnatoKarp Partners LLC lifted its stake in shares of GlaxoSmithKline by 1.4% in the second quarter. PagnatoKarp Partners LLC now owns 5,812 shares of the pharmaceutical company’s stock worth $253,000 after acquiring an additional 80 shares in the last quarter. Institutional investors and hedge funds own 9.83% of the company’s stock.

GlaxoSmithKline (NYSE:GSK) traded down $0.25 during mid-day trading on Monday, reaching $34.99. The company’s stock had a trading volume of 7,000,000 shares, compared to its average volume of 5,060,000. GlaxoSmithKline has a 1 year low of $34.52 and a 1 year high of $44.53. The company has a debt-to-equity ratio of 2.96, a quick ratio of 0.44 and a current ratio of 0.64. The stock has a market capitalization of $84,940.00, a P/E ratio of 12.50, a PEG ratio of 1.95 and a beta of 0.97.

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 11th. Stockholders of record on Friday, November 10th will be given a $0.5037 dividend. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.49. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $2.01 annualized dividend and a dividend yield of 5.76%. GlaxoSmithKline’s dividend payout ratio is presently 156.69%.

WARNING: This report was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/glaxosmithkline-plc-gsk-given-consensus-rating-of-hold-by-analysts/1768579.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.